Vimarsana
Biggest News Aggregation in the World

Page 49 - Technical Operations News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Technical Operations. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Technical Operations Today - Breaking & Trending Today

American Airlines partners with Safran to reduce its environmental footprint with lighter, more efficient brakes - Vimarsana News

American Airlines partners with Safran to reduce its environmental footprint with lighter, more efficient brakes

Lighter than steel brakes, with up to 700 pounds (320 kg) of weight savings per aircraft, this upgrade to the Safran Landing Systems carbon brakes configuration will help American meet its sustainability commitments by reducing its greenhouse gas (GHG) emissions by 77 tons per Boeing 737NG aircraft every year. Thanks…

American Airlines' Safety Management System - Vimarsana News

American Airlines' Safety Management System

NORTHAMPTON, MA / ACCESSWIRE / December 15, 2022 / The safety of our customers and team members is guided by our Safety Management System (SMS), an organizationwide approach to identifying and managing

Renibus Therapeutics Strengthens Leadership Team with Asha Ramdas as SVP, Program Management, Technical Operations and Manufacturing - Vimarsana News

Renibus Therapeutics Strengthens Leadership Team with Asha Ramdas as SVP, Program Management, Technical Operations and Manufacturing

/PRNewswire/ -- Renibus Therapeutics, Inc., ("Renibus"), a clinical-stage biotechnology company developing breakthrough products for cardiorenal diseases,...

Time to CAR T-cell Therapy May Impact Outcomes for Patients With Relapsed/Refractory Large B-cell Lymphoma in New CIBMTR Analysis - Vimarsana News

Time to CAR T-cell Therapy May Impact Outcomes for Patients With Relapsed/Refractory Large B-cell Lymphoma in New CIBMTR Analysis

11.12.2022 - Kite, a Gilead Company (Nasdaq: GILD), today announced results from one of the largest real-world analyses of patients who received CAR T-cell therapy assessing the impact of time from leukapheresis to infusion ('vein-to-vein' time) for Yescarta ...

Time to CAR T-cell Therapy May Impact Outcomes for Patients With Relapsed/Refractory Large B-cell Lymphoma in New CIBMTR Analysis - Vimarsana News

Time to CAR T-cell Therapy May Impact Outcomes for Patients With Relapsed/Refractory Large B-cell Lymphoma in New CIBMTR Analysis

– Kite’s Manufacturing Time for Yescarta® in the U.S. is Median of 7-Days from Start of Cell Enrichment to Harvest, with an Overall 16-Day Turnaround Time (Leukapheresis to Product Release) – – CIBMTR Analysis Finds Median ‘Vein-to-Vein’ Time (Leukapheresis to Infusion) in Real World Setting is 27-Days for Yescarta in the U.S. – – In Same Analysis, Shorter Vein-to-Vein Time Associated with 60% Complete Response Rate in Patients Treated with Yescarta at Median Follow-Up of 24.2 Months –